{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:32:08Z","timestamp":1793021528763,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-024-07284-1","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T10:51:39Z","timestamp":1736506299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway"],"prefix":"10.1038","volume":"8","author":[{"given":"Yuwen","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangrui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoquan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enguang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Shui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-5293","authenticated-orcid":false,"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7485-2017","authenticated-orcid":false,"given":"Lanlan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-591X","authenticated-orcid":false,"given":"Zhiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"7284_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"7284_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","volume":"81","author":"R Cathomas","year":"2022","unstructured":"Cathomas, R. et al. The 2021 Updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur. Urol. 81, 95\u2013103 (2022).","journal-title":"Eur. Urol."},{"key":"7284_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"7284_CR4","doi-asserted-by":"publisher","first-page":"94ra70","DOI":"10.1126\/scitranslmed.3002394","volume":"3","author":"DA Chan","year":"2011","unstructured":"Chan, D. A. et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci. Transl. Med. 3, 94ra70 (2011).","journal-title":"Sci. Transl. Med."},{"key":"7284_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32101-w","volume":"13","author":"Y Tan","year":"2022","unstructured":"Tan, Y. et al. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells. Nat. Commun. 13, 4554 (2022).","journal-title":"Nat. Commun."},{"key":"7284_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ctrv.2016.03.005","volume":"45","author":"F Massari","year":"2016","unstructured":"Massari, F. et al. Metabolic phenotype of bladder cancer. Cancer Treat. Rev. 45, 46\u201357 (2016).","journal-title":"Cancer Treat. Rev."},{"key":"7284_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.tibs.2014.06.005","volume":"39","author":"KC Patra","year":"2014","unstructured":"Patra, K. C. & Hay, N. The pentose phosphate pathway and cancer. Trends Biochem. Sci. 39, 347\u2013354 (2014).","journal-title":"Trends Biochem. Sci."},{"key":"7284_CR8","doi-asserted-by":"publisher","unstructured":"Giacomini, I., Ragazzi, E., Montopoli, M. & Pasut, G. The pentose phosphate pathway and its involvement in cisplatin resistance. Int. J. Mol. Sci. 21, https:\/\/doi.org\/10.3390\/ijms21030937 (2020).","DOI":"10.3390\/ijms21030937"},{"key":"7284_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13732","volume":"8","author":"J Zhang","year":"2017","unstructured":"Zhang, J. et al. c-Src phosphorylation and activation of hexokinase promotes tumorigenesis and metastasis. Nat. Commun. 8, 13732 (2017).","journal-title":"Nat. Commun."},{"key":"7284_CR10","doi-asserted-by":"publisher","first-page":"25113","DOI":"10.18632\/oncotarget.7159","volume":"7","author":"Y Jin","year":"2016","unstructured":"Jin, Y. et al. Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation. Oncotarget 7, 25113\u201325124 (2016).","journal-title":"Oncotarget"},{"key":"7284_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.642229","volume":"11","author":"X Wei","year":"2021","unstructured":"Wei, X. et al. Targeting ACLY attenuates tumor growth and acquired cisplatin resistance in ovarian cancer by inhibiting the PI3K-AKT pathway and activating the AMPK-ROS pathway. Front. Oncol. 11, 642229 (2021).","journal-title":"Front. Oncol."},{"key":"7284_CR12","doi-asserted-by":"publisher","unstructured":"Afonso, J. & Gon\u00e7alves, C. Glucose metabolism reprogramming in bladder cancer: Hexokinase 2 (HK2) as prognostic biomarker and target for bladder cancer therapy. Cancers 15 https:\/\/doi.org\/10.3390\/cancers15030982 (2023).","DOI":"10.3390\/cancers15030982"},{"key":"7284_CR13","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.celrep.2020.03.005","volume":"30","author":"H Ma","year":"2020","unstructured":"Ma, H. et al. c-Src promotes tumorigenesis and tumor progression by activating PFKFB3. Cell Rep. 30, 4235\u20134249.e4236 (2020).","journal-title":"Cell Rep."},{"key":"7284_CR14","doi-asserted-by":"publisher","first-page":"5438","DOI":"10.1158\/0008-5472.CAN-21-0613","volume":"81","author":"C Temps","year":"2021","unstructured":"Temps, C. et al. A conformation selective mode of inhibiting SRC improves drug efficacy and tolerability. Cancer Res. 81, 5438\u20135450 (2021).","journal-title":"Cancer Res."},{"key":"7284_CR15","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1042\/BCJ20160613","volume":"473","author":"K Nam","year":"2016","unstructured":"Nam, K., Oh, S. & Shin, I. Ablation of CD44 induces glycolysis-to-oxidative phosphorylation transition via modulation of the c-Src-Akt-LKB1-AMPKalpha pathway. Biochem. J. 473, 3013\u20133030 (2016).","journal-title":"Biochem. J."},{"key":"7284_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/cac2.12274","volume":"42","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. The Fibrillin-1\/VEGFR2\/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells. Cancer Commun 42, 245\u2013265 (2022).","journal-title":"Cancer Commun"},{"key":"7284_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2147\/OTT.S358008","volume":"15","author":"M Li","year":"2022","unstructured":"Li, M., Che, N., Jin, Y., Li, J. & Yang, W. CDKN3 overcomes bladder cancer cisplatin resistance via LDHA-dependent glycolysis reprogramming. OncoTargets Ther. 15, 299\u2013311 (2022).","journal-title":"OncoTargets Ther."},{"key":"7284_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.omtn.2020.10.031","volume":"23","author":"H Yu","year":"2021","unstructured":"Yu, H. et al. ALKBH5 inhibited cell proliferation and sensitized bladder cancer cells to cisplatin by m6A-CK2\u03b1-mediated glycolysis. Mol. Ther. Nucleic Acids 23, 27\u201341 (2021).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"7284_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09438-9","volume":"12","author":"T Xu","year":"2022","unstructured":"Xu, T. et al. Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time. Sci. Rep. 12, 5518 (2022).","journal-title":"Sci. Rep."},{"key":"7284_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0092-8674(84)90308-8","volume":"37","author":"RC Parker","year":"1984","unstructured":"Parker, R. C., Varmus, H. E. & Bishop, J. M. Expression of v-src and chicken c-src in rat cells demonstrates qualitative differences between pp60v-src and pp60c-src. Cell 37, 131\u2013139 (1984).","journal-title":"Cell"},{"key":"7284_CR21","doi-asserted-by":"crossref","unstructured":"Smith, H. W. et al. An ErbB2\/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. Nature communications 10, 2901 (2019).","DOI":"10.1038\/s41467-019-10681-4"},{"key":"7284_CR22","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1158\/0008-5472.CAN-10-1605","volume":"71","author":"H Cai","year":"2011","unstructured":"Cai, H., Babic, I., Wei, X., Huang, J. & Witte, O. N. Invasive prostate carcinoma driven by c-Src and androgen receptor synergy. Cancer Res. 71, 862\u2013872 (2011).","journal-title":"Cancer Res."},{"key":"7284_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccr.2004.09.001","volume":"6","author":"R Ishizawar","year":"2004","unstructured":"Ishizawar, R. & Parsons, S. J. c-Src and cooperating partners in human cancer. Cancer Cell 6, 209\u2013214 (2004).","journal-title":"Cancer Cell"},{"key":"7284_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101059","volume":"73","author":"F Li","year":"2024","unstructured":"Li, F. et al. Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer. Drug Resist. Updat. 73, 101059 (2024).","journal-title":"Drug Resist. Updat."},{"key":"7284_CR25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.neo.2015.09.003","volume":"17","author":"A Mukherjee","year":"2015","unstructured":"Mukherjee, A. et al. Lysophosphatidic acid up-regulates hexokinase II and glycolysis to promote proliferation of ovarian cancer cells. Neoplasia 17, 723\u2013734 (2015).","journal-title":"Neoplasia"},{"key":"7284_CR26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41419-019-1549-6","volume":"10","author":"T Shi","year":"2019","unstructured":"Shi, T. et al. B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death Dis. 10, 308 (2019).","journal-title":"Cell Death Dis."},{"key":"7284_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ccr.2013.06.014","volume":"24","author":"KC Patra","year":"2013","unstructured":"Patra, K. C. et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24, 213\u2013228 (2013).","journal-title":"Cancer Cell"},{"key":"7284_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s13577-019-00285-x","volume":"33","author":"S Liu","year":"2020","unstructured":"Liu, S., Chen, Q. & Wang, Y. MiR-125b-5p suppresses the bladder cancer progression via targeting HK2 and suppressing PI3K\/AKT pathway. Hum. Cell 33, 185\u2013194 (2020).","journal-title":"Hum. Cell"},{"key":"7284_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrd3504","volume":"10","author":"MG Vander Heiden","year":"2011","unstructured":"Vander Heiden, M. G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 10, 671\u2013684 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"7284_CR30","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.7150\/thno.51797","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang, D. et al. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Theranostics 11, 2860\u20132875 (2021).","journal-title":"Theranostics"},{"key":"7284_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24452","volume":"36","author":"X Pan","year":"2022","unstructured":"Pan, X., Chen, G. & Hu, W. Piperlongumine increases the sensitivity of bladder cancer to cisplatin by mitochondrial ROS. J. Clin. Lab. Anal. 36, e24452 (2022).","journal-title":"J. Clin. Lab. Anal."},{"key":"7284_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13046-019-1166-3","volume":"38","author":"WC Huang","year":"2019","unstructured":"Huang, W. C., Kuo, K. T., Wang, C. H. & Yeh, C. T. Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src\/CD155\/MIF functional pathway. J. Exp. Clin. cancer Res. 38, 180 (2019).","journal-title":"J. Exp. Clin. cancer Res."},{"key":"7284_CR33","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/0008-5472.CAN-10-0730","volume":"71","author":"S Thomas","year":"2011","unstructured":"Thomas, S. et al. Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res. 71, 832\u2013841 (2011).","journal-title":"Cancer Res."},{"key":"7284_CR34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41416-022-01794-7","volume":"127","author":"Z Zhou","year":"2022","unstructured":"Zhou, Z. et al. SBSN drives bladder cancer metastasis via EGFR\/SRC\/STAT3 signalling. Br. J. Cancer 127, 211\u2013222 (2022).","journal-title":"Br. J. Cancer"},{"key":"7284_CR35","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/nbt.2017","volume":"29","author":"T Anastassiadis","year":"2011","unstructured":"Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H. & Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039\u20131045 (2011).","journal-title":"Nat. Biotechnol."},{"key":"7284_CR36","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1038\/s41388-022-02487-4","volume":"41","author":"SG Pelaz","year":"2022","unstructured":"Pelaz, S. G. & Tabernero, A. Src: coordinating metabolism in cancer. Oncogene 41, 4917\u20134928 (2022).","journal-title":"Oncogene"},{"key":"7284_CR37","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1021\/acs.jmedchem.6b00065","volume":"59","author":"C Fraser","year":"2016","unstructured":"Fraser, C. et al. Rapid discovery and structure-activity relationships of pyrazolopyrimidines that potently suppress breast cancer cell growth via src kinase inhibition with exceptional selectivity over ABL kinase. J. Med. Chem. 59, 4697\u20134710 (2016).","journal-title":"J. Med. Chem."},{"key":"7284_CR38","doi-asserted-by":"publisher","first-page":"6443","DOI":"10.21873\/anticanres.13858","volume":"39","author":"MVS Amaral","year":"2019","unstructured":"Amaral, M. V. S. et al. Establishment of drug-resistant cell lines as a model in experimental oncology: a review. Anticancer Res. 39, 6443\u20136455 (2019).","journal-title":"Anticancer Res."},{"key":"7284_CR39","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1158\/0008-5472.CAN-14-3735","volume":"75","author":"M Liu","year":"2015","unstructured":"Liu, M. et al. Heterochromatin protein HP1\u03b3 promotes colorectal cancer progression and is regulated by miR-30a. Cancer Res. 75, 4593\u20134604 (2015).","journal-title":"Cancer Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07284-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07284-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07284-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T11:06:10Z","timestamp":1736507170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07284-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7284"],"URL":"https:\/\/doi.org\/10.1038\/s42003-024-07284-1","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"25 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experimental protocols were approved by the Lanzhou University Second Hospital Ethics Board (approval number:2020A-053).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"36"}}